Clinical trial
A Study of Pertuzumab in Combination With Herceptin in Patients With HER2…
NCT00545688 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00545688 |
|---|---|
| Title | A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer. |
| Official title | A Randomized, Open Label Study to Compare the Complete Pathological Response Rate Achieved With 4 Combinations of Herceptin, Docetaxel and Pertuzumab in Patients With Locally Advanced, Inflammatory or Early Stage HER2 Positive Breast Cancer |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Herceptin, Docetaxel, Pertuzumab |
| Enrollment | 417 |
| Start date | Jun 26, 2006 |
| Primary completion | Sep 22, 2014 |
| Completion | Sep 22, 2014 |
| First posted | Oct 17, 2007 |
| Last update posted | Aug 15, 2017 |
| Countries | Australia, Austria, Brazil, Canada, Israel, Italy, Mexico, Peru, Poland, Russia, South Korea, Spain and 6 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: